“…We previously reported that compromised decidual health and function in p53 d/d females are reflected in premature decidual senescence, increased rates of spontaneous PTB, and highly increased response to a small dose of LPS (4). To assess the effects of Met treatment on decidual health, we first examined the status of γH2AX associated with DNA damage followed by staining of senescence-associated β-galactosidase (SA-β-gal), 2 markers of decidual senescence (25) metformin (Met) is widely used as a first-line therapy for diabetes to increase insulin sensitivity (7,8). Its off-label use in ovulation induction in women with polycystic ovary syndrome is supported by its safety reports in pregnancy (9,10).…”